Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma

This is an open-label, single arm, multicenter, Phase II clinical study to investigate the efficacy and safety profiles of autologous ATL administration in HCC patients after curative treatment. Among all the eligible patients, ratio of 7:2:1 for Stage I:II:IIIa of the HCC will be the enrolled strategy of the study to reflect the results of the previous study (Lee, Lee et al. 2015).

Trial Details

NCT ID
NCT05304481
Phase
PHASE2
Sponsor
Lukas Biomedical Inc.
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • ATL administration
Locations (sample)
  • Hualien City, Taiwan, Taiwan|23.97694,121.60444
  • New Taipei City, Taiwan, Taiwan
  • Taipei, Taiwan, Taiwan|25.05306,121.52639
  • Taipei, Taiwan, Taiwan|25.05306,121.52639
  • Kaohsiung City, Taiwan|22.61626,120.31333

Key Eligibility Criteria

  • Patients must be able to understand and sign the informed consent documents and aware of the investigational nature of the study.
  • Patient is ≥ 20 years old.
  • Patient has been diagnosed as HCC by pathological data or radiological test in the stage of I, II or IIIa according to the American Joint Committee…
  • Patient is scheduled to or has received tumor removal by curative treatments (e.g., surgical operation, percutaneous ethanol injection \[PEI\], mic…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →